Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Food Sci ; 73(9): H241-5, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19021808

RESUMO

Fruit and vegetable intake is typically low for type 2 diabetics, possibly due to a perceived adverse effect on glycemic control. Cranberry juice (CBJ) may represent an attractive means for increasing fruit intake and simultaneously affording positive health benefits. This single cross-over design compared metabolic responses of type 2 diabetics (n= 12) to unsweetened low-calorie CBJ (LCCBJ; 19 Cal/240 mL), carbohydrate sweetened normal calorie CBJ (NCCBJ; 120 Cal/240 mL), isocaloric low-calorie sugar water control (LCC), and isocaloric normal calorie sugar water control (NCC) interventions. CBJ flavonols and anthocyanins, and proanthocyanidins were quantified with HPLC, LC-MS, and MALDI-TOF that includes an original characterization of several large oligomeric proanthocyanidins. Blood glucose peaked 30 min postingestion after NCCBJ and NCC at 13.3 +/- 0.5 and 12.8 +/- 0.9 (mmol/L), and these responses were significantly greater than the LCCBJ and LCC peaks of 8.1 +/- 0.5 and 8.7 +/- 0.5, respectively. Differences in glycemic response remained significant 60 min, but not 120 min postingestion. Plasma insulin values 60 min postingestion for NCCBJ and NCC interventions were 140 +/- 19 and 151 +/- 18 (pmol/L), respectively, and significantly greater than the LCCBJ and LCC values of 56 +/- 10 and 54 +/- 10; differences were not significant 120 min postingestion. Metabolic responses within the 2 high and 2 low-calorie beverages were virtually identical; however, exposure to potentially beneficial nutrients was greater with CBJ. Relative to conventionally sweetened preparation, LCCBJ provides a favorable metabolic response and should be useful for promoting increased fruit consumption among type 2 diabetics or others wishing to limit carbohydrate intake.


Assuntos
Bebidas , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Vaccinium macrocarpon , Idoso , Glicemia/efeitos dos fármacos , Índice de Massa Corporal , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Dieta para Diabéticos , Ingestão de Energia , Feminino , Frutas , Índice Glicêmico , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Verduras
2.
Mol Carcinog ; 6(4): 243-51, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1362493

RESUMO

A number of primary human breast carcinomas exhibit amplification of the chromosome 11 region containing the int-2/fgf-3 proto-oncogene, and progression of breast cancer has been correlated with int-2 amplification or with certain restriction fragment length polymorphisms (RFLPs) of the int-2 gene. Using the polymerase chain reaction (PCR), we obtained the int-2 coding sequences from six primary tumors, four of which exhibited amplification of the int-2 gene and one of which exhibited amplification of the neu gene. The majority of these tumors (five of six) were aggressive, as judged by their early recurrence, metastasis, or both. Nucleotide sequencing of PCR products revealed that previously described BamHI and PstI RFLPs of the int-2 gene, as well as a new polymorphism at position 9154, were located within the intron between the second and third exons. A seventh tumor was used to localize one of the PstI RFLPs 5 bp from the splice-acceptor site of the third exon. However, none of the tumor DNAs analyzed showed differences in the int-2 protein coding regions when compared with normal placenta DNA. These results imply that aggressive human breast cancers encode an unaltered form of the int-2 protein.


Assuntos
Neoplasias da Mama/genética , Fatores de Crescimento de Fibroblastos , Proteínas Proto-Oncogênicas/genética , Proto-Oncogenes , Sequência de Bases , Southern Blotting , Neoplasias da Mama/patologia , Cromossomos Humanos Par 11 , DNA/genética , DNA/isolamento & purificação , DNA de Neoplasias/genética , DNA de Neoplasias/isolamento & purificação , Desoxirribonuclease BamHI , Desoxirribonucleases de Sítio Específico do Tipo II , Feminino , Fator 3 de Crescimento de Fibroblastos , Humanos , Dados de Sequência Molecular , Oligodesoxirribonucleotídeos , Placenta/fisiologia , Reação em Cadeia da Polimerase/métodos , Polimorfismo de Fragmento de Restrição , Gravidez , Proteínas Tirosina Quinases/genética , Proto-Oncogene Mas , Homologia de Sequência do Ácido Nucleico
3.
Cancer Res ; 50(18): 5911-8, 1990 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-1975511

RESUMO

We have examined the DNA obtained from 100 primary breast carcinomas for oncogene markers which might have predictive value for poor prognosis. Ninety-six of the tumors were analyzed for the presence of restriction fragment length polymorphisms (RFLPs) previously identified in the int-2 gene. An 8.4-kilobase BamHI fragment and a 3.9-kilobase PstI fragment specific for the int-2 gene, in the absence of other restriction fragments, was found in 17 of 50 (34%) lymph node-negative patients and in 27 of 44 (61%) lymph node-positive patients. This combination of int-2 RFLPs (8.4/3.9) was found in a significantly different proportion (P = 0.02) of patients with greater than 3 positive lymph nodes compared to patients with fewer positive lymph nodes, suggesting that these RFLPs may be valuable for distinguishing among node-negative patients for chemotherapy. In contrast, the observed low frequency of int-1, int-2, neu, and c-myc amplification limited their usefulness as clinical predictors of disease recurrence.


Assuntos
Neoplasias da Mama/genética , Fatores de Crescimento de Fibroblastos , Proteínas Proto-Oncogênicas/genética , Proto-Oncogenes , Proteínas de Peixe-Zebra , Feminino , Fator 3 de Crescimento de Fibroblastos , Amplificação de Genes , Genótipo , Humanos , Polimorfismo de Fragmento de Restrição , Proteínas Proto-Oncogênicas c-myc , Receptor ErbB-2 , Proteínas Wnt , Proteína Wnt1
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA